ReCode Therapeutics Initiates Phase 1 Trial for mRNA Therapy in Primary Ciliary Dyskinesia

ReCode Therapeutics has treated the first patient with RCT1100, an mRNA-based therapy in a Phase 1 study for primary ciliary dyskinesia (PCD) caused by DNAI1 gene mutations. PCD is a rare genetic disease affecting cilia function in the respiratory tract, leading to chronic infections. The therapy aims to address this issue using tissue-specific delivery for mRNA and gene correction.